JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target
Benzinga Newsdesk 2 months ago
NewsInitiationAnalyst RatingsPrice Target
JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.
JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.